论文部分内容阅读
目的:观察益赛普治疗白塞病的疗效和安全性。方法:回顾性分析,18例活动性白塞病患者(BD)分别采用常规治疗:即使用糖皮质激素、沙利度胺治疗,和使用生物制剂-益赛普治疗。评价其疗效和安全性。分为临床和实验室指标。结果:使用益赛普治疗的患者缓解时间和复发率均较使用糖皮质激素、沙利度胺者明显降低(P<0.05)临床指标包括:口腔溃疡、生殖器溃疡、结节性红斑、眼色素膜炎和关节炎。实验室指标:红细胞沉降率(ESR)和C反应蛋白(CRP)。结论:益赛普治疗BD患者临床疗效较糖皮质激素、沙利度胺好,副作用较少。
Objective: To observe the efficacy and safety of Ipsap in the treatment of Behcet’s disease. Methods: Retrospectively analyzed, 18 patients with active Behcet’s disease (BD) were treated with conventional therapy, respectively: with glucocorticoid, thalidomide, and biologic-ixapril. Evaluate its efficacy and safety. Divided into clinical and laboratory indicators. Results: The response time and recurrence rate of patients treated with Isoprost were significantly lower than those treated with glucocorticoid and thalidomide (P <0.05). Clinical indicators included oral ulcer, genital ulcer, erythema nodosum, Membranes and arthritis. Laboratory indicators: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Conclusion: The clinical efficacy of ixapril in the treatment of BD patients is better than that of glucocorticoid and thalidomide, with fewer side effects.